Compare JEOL Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 16.17%
- Healthy long term growth as Operating profit has grown by an annual rate 34.62%
- Company has very low debt and has enough cash to service the debt requirements
- NET SALES(HY) At JPY 89,659 MM has Grown at -10.34%
- ROCE(HY) Lowest at 11.19%
- INTEREST(Q) At JPY 27 MM has Grown at 22.73%
2
With ROE of 19.07%, it has a fair valuation with a 2.10 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 335,272 Million (Mid Cap)
11.00
NA
0.00%
-0.17
19.07%
2.24
Revenue and Profits:
Net Sales:
47,745 Million
(Quarterly Results - Dec 2025)
Net Profit:
7,641 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.27%
0%
7.27%
6 Months
29.48%
0%
29.48%
1 Year
40.73%
0%
40.73%
2 Years
0.87%
0%
0.87%
3 Years
60.19%
0%
60.19%
4 Years
8.42%
0%
8.42%
5 Years
8.42%
0%
8.42%
JEOL Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.03%
EBIT Growth (5y)
34.62%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.37
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
1.32
Tax Ratio
25.13%
Dividend Payout Ratio
29.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.02%
ROE (avg)
16.17%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
2.10
EV to EBIT
9.42
EV to EBITDA
8.00
EV to Capital Employed
2.33
EV to Sales
1.52
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
24.78%
ROE (Latest)
19.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
47,745.00
49,118.00
-2.80%
Operating Profit (PBDIT) excl Other Income
10,809.00
11,478.00
-5.83%
Interest
27.00
28.00
-3.57%
Exceptional Items
0.00
0.00
Consolidate Net Profit
7,641.00
9,020.00
-15.29%
Operating Profit Margin (Excl OI)
198.20%
213.40%
-1.52%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -2.80% vs 28.72% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -15.29% vs 242.97% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
196,695.00
174,336.00
12.83%
Operating Profit (PBDIT) excl Other Income
40,803.00
32,278.00
26.41%
Interest
120.00
88.00
36.36%
Exceptional Items
-12,315.00
-727.00
-1,593.95%
Consolidate Net Profit
18,688.00
21,704.00
-13.90%
Operating Profit Margin (Excl OI)
181.10%
157.90%
2.32%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 12.83% vs 7.16% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -13.90% vs 21.73% in Mar 2024
About JEOL Ltd. 
JEOL Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






